Top medical benefit drugs by commercial PMPM spending U.S. 2022

Leading medical benefit drugs in the U.S. by commercial PMPM spending in 2022 (in U.S. dollars)

Leading medical benefit drugs by commercial PMPM spending U.S. 2022

Last update:

Oct 12, 2023

Author:

��ƽ�� Research Department

Region:

United States

Survey time period:

From 01/01/2022 to 31/12/2022

In 2022, commercial insurance spending on the drug Remicade was at 1.42 U.S. dollars per member per month (PMPM) in the United States. This statistic illustrates the leading medical benefit drugs in the United States, based on PMPM spending.

We’re happy to help

Get in touch with us for additional information

Feel free to contact us anytime. We will respond to your inquiry as quickly as possible.

Get in touch

�����ƽ��

Leading medical benefit drugs in the U.S. by commercial PMPM spending in 2022 (in U.S. dollars)

Get in touch with us for additional information

��ƽ��